Idea or Concept – Talk Bio

Coloplast; Executive Leadership Team; ELT changes; Interventional Urology; People & Culture; Kevin Hardage; Tommy Johns; leadership transition; management changes

Biopharma’s Winners and Losers of 2025 – Endpoints News recap

4 weeks ago talkbio0Tagged 2025, Biopharma, Endpoints, Kyle LaHucik, Losers, movers, News [Publication Type], Pharma, Post-Hoc Live, Review [Publication Type], winners

Endpoints News; winners and losers; 2025; biopharma; Post-Hoc Live; Kyle LaHucik; year in review; biotech; pharma; stock movers

No public results for “Take the Biopharma Sentiment Index” Q1 2026 yet

4 weeks ago talkbio0Tagged Attitude, Biological Science Disciplines, Biopharma, biopharma executives, Biopharma Sentiment Index, geopolitical risk, M&A activity, Q1 2026, Sentiment, Surveys

Biopharma Sentiment Index; Q1 2026; biopharma executives; life sciences sentiment; 2026 outlook; M&A activity; AI in biopharma; geopolitical risk; survey data

Immunovant Announces Pricing of $550 Million Common Stock Financing

1 month ago talkbio0Tagged Capital, equity financing, financing characteristics, Immunovant, IMVT, IMVT-1402, Leerink Partners, Roivant Sciences

Immunovant; IMVT; common stock offering; $550 million financing; equity financing; underwritten offering; IMVT-1402; Roivant Sciences; Leerink Partners; biotech capital raise

Spotlight On: It’s Raining AI Devices as Regulatory Storm Reshapes Digital Health

1 month ago talkbio0Tagged 2025, Accountability, AI-enabled, clinical oversight, digital health regulation, digital mental health devices, draft guidance, EU, EU AI Act health, Generative AI, Health care facility, Medical Devices, Regulation, Software as a Medical Device, United States Food and Drug Administration

AI-enabled medical devices; digital health regulation 2025; FDA AI draft guidance; EU AI Act health; generative AI in healthcare; SaMD regulation; clinical oversight of AI; AI accountability in healthcare; digital mental health devices

J&J-backed Cellular Origins raises $40M for cell therapy manufacturing

1 month ago talkbio0Tagged cell therapy manufacturing, Cellular Origins, Constellation platform, cyclic adenosine-5'-trimetaphosphate, Groups, Johnson & Johnson, Manufacturing, Purpura, Thrombotic Thrombocytopenic, robotic automation

Cellular Origins; Johnson & Johnson; Series A; $40 million; cell therapy manufacturing; Constellation platform; robotic automation; ATMP; TTP Group; scalable manufacturing

Kymera’s oral “Dupixent-in-a-pill” KT-621 shows strong early eczema results

1 month ago talkbio0Tagged BroADen Phase 1b trial, Clinical, Dermatitis, Atopic, Dupixent, Dupixent-in-a-pill, Eczema, KT-621, Kymera Therapeutics, Oral cavity, STAT6 degrader, type 2 inflammation

Kymera Therapeutics; KT-621; Dupixent-in-a-pill; oral STAT6 degrader; atopic dermatitis; eczema; BroADen Phase 1b trial; Dupixent rival; Type 2 inflammation; early clinical data